META

META Pharmaceuticals Inc., an original drug company focusing on the research and development of drugs for autoimmune diseases, is composed of a team of biomedical doctors from Cornell University in the United States. It is co-invested and incubated by XtalPi, a pioneer in AI-driven drug discovery, and Forcefield Ventures, a well-known venture capital firm. Based on cutting-edge emerging biological theories, META achieves effective regulation of immune system functions by modulating the vitality of cellular metabolism. It aims to develop safer and more effective novel targets for autoimmune diseases, focusing on first-in-class innovative drug research and development to provide urgently needed medications for patients worldwide.META has established an in-depth collaboration with XtalPi in AI-driven new drug research and development. By integrating fundamental theoretical research capabilities with AI-powered one-stop drug discovery capabilities, they have jointly pioneered a new paradigm for drug development that transforms AI + medical basic research achievements into AI-driven pharmaceuticals.